Amphastar Pharmaceuticals (AMPH) 10-K2023 FY Annual report

Filed: 29 Feb 24, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accreted, accretion, America, anniversary, annum, Aspart, assumption, BAQSIMI, baqsimi®, bifurcated, bifurcation, BofA, budgetary, bypassing, Cancer, Carnegie, Cencora, chairperson, Chamber, CMO, Colon, compact, consecutive, conversion, creation, cybersecurity, daily, deepen, Degludec, deprecation, disadvantage, disaggregated, Eugia, Fargo, FDIC, feature, floor, Florida, footprint, freedom, freely, freestanding, fundamental, highest, ICBC, imaging, implicated, indenture, inextricably, Infusion, instrument, Iowa, judgement, junior, Medefil, Mellon, Middle, Milestone, Montana, Morgan, MSA, myocardial, navigating, Nevada, Nordisk, Novo, Oregon, Overnight, perfusion, pharmacokinetic, pharmacologic, pivotal, professional, promptly, quadruple, radionuclide, rank, ready, redeem, redeemed, redemption, residing, REXTOVYTM, setup, SOFR, sublimit, Subtopic, Swing, swingline, syndicated, Tennessee, theoretical, tradeable, trustee, TSA, unamortized, underwriting, University, unsecured, vision, Washington

Removed: abated, accessing, account, actuation, adjusting, Afrezza, Answer, birth, comprehension, contact, contingency, contractually, CRL, curtail, educate, enforced, equitable, facilitating, fulfilled, HITECH, inclusive, infection, instituting, investigating, Jason, join, LIBOR, mission, modernize, modifying, Montreal, narrow, noting, occasionally, outbreak, pace, PPE, prioritization, protective, renewing, resignation, resigned, retired, sexual, Shandell, shift, skill, structured, subsided, synthesize, transport, transportation, unchanged, verification

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AMPH transcripts

AMPH similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)	Registration Statement (Form S-8 No. 333-197054) pertaining to the 1999-2002 Stock Option/Stock Issuance Plans, the Amended and Restated 2005 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan of Amphastar Pharmaceuticals, Inc.,

(2)	Registration Statement (Form S-8 No. 333-203017) pertaining to the Amended and Restated 2005 Equity Incentive Award Plan of Amphastar Pharmaceuticals, Inc.,

(3)	Registration Statement (Form S-8 No. 333-205470) pertaining to the 2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc.,

(4)	Registration Statement (Form S-8 No. 333-210213) pertaining to the 2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc.,

(5)	Registration Statement (Form S-8 No. 333-216700) pertaining to the 2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc.,

(6)	Registration Statement (Form S-8 No. 333-223651) pertaining to the 2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc.,

(7)	Registration Statement (Form S-8 No. 333-230330) pertaining to the 2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc.,

(8)	Registration Statement (Form S-8 No. 333-237223) pertaining to the 2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc.,

(9)	Registration Statement (Form S-8 No. 333-254293) pertaining to the 2015 Amended and Restated Equity Incentive Plan of Amphastar Pharmaceuticals, Inc.,

(10)	Registration Statement (Form S-3 No. 333-260916) of Amphastar Pharmaceuticals, Inc.,

(11)	Registration Statement (Form S-8 No. 333-263491) pertaining to the Amended and Restated 2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc.; and

(12)	Registration Statement (Form S-8 No. 333-270180) pertaining to the Amended and Restated 2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc;

of our reports dated February 29, 2024, with respect to the consolidated financial statements of Amphastar Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Amphastar Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Amphastar Pharmaceuticals, Inc. for the year ended December 31, 2023.

/s/ Ernst & Young LLP

Irvine, California

February 29, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.